NewsBenzingaErnexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine Benzinga 2026.09.30 12:40 (GMT+0) Open on Benzinga Other news Barclays Maintains Overweight on Crown Castle, Raises Price Target to $86 Barclays Maintains Overweight on American Tower, Raises Price Target to $199 Truist Securities Maintains Hold on Expedia Group, Lowers Price Target to $288 Wells Fargo Maintains Equal-Weight on Chesapeake Utilities, Raises Price Target to $136 Capricor Therapeutics Stock Surges: What's Going On? Wells Fargo Maintains Overweight on Woodward, Lowers Price Target to $430
